Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment
Sponsor: Xiangya Hospital of Central South University
Summary
This multicenter study evaluates the effectiveness and safety of a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C who relapsed after prior direct-acting antiviral therapy. The study assesses the rate of sustained virologic response after treatment, along with changes in liver function and overall safety. It also explores whether clinical factors such as liver cirrhosis, viral genotype, and the use of ribavirin influence treatment outcomes, aiming to better define this regimen as a salvage therapy option.
Official title: A Multicenter Study Evaluating the Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Chronic Hepatitis C Patients With Relapse After Direct-Acting Antiviral Therapy
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2022-01-01
Completion Date
2027-12-31
Last Updated
2026-05-04
Healthy Volunteers
No
Conditions
Locations (1)
Xiangya Hospital of Central South University
Changsha, Hunan, China